摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,7-Dihydro-9H-[1,3]diazepino[1,2,3-cd]purine-9,11(10H)-dione | 131489-67-3

中文名称
——
中文别名
——
英文名称
4,7-Dihydro-9H-[1,3]diazepino[1,2,3-cd]purine-9,11(10H)-dione
英文别名
1,3,6,8-tetrazatricyclo[6.4.1.04,13]trideca-2,4(13),10-triene-5,7-dione
4,7-Dihydro-9H-[1,3]diazepino[1,2,3-cd]purine-9,11(10H)-dione化学式
CAS
131489-67-3
化学式
C9H8N4O2
mdl
——
分子量
204.188
InChiKey
XRMRTBAVAQPJKZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    67.2
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    参考文献:
    名称:
    不饱和和碳环核苷类似物:合成,抗肿瘤和抗病毒活性。
    摘要:
    制备了一系列核苷的不饱和类似物,并研究了它们的细胞毒性,抗肿瘤和抗病毒活性。用(E)-1,4-二氯-2-丁烯烷基化胞嘧啶,得到氯衍生物2f,将其水解成醇2h。胞嘧啶,腺嘌呤,2-氨基-6-氯嘌呤,胸腺嘧啶和(Z)-1,4-氯-2-丁烯得到化合物4c-f,水解后得到醇4a,4b,4g和4h。烯烃4d和4e环化成杂环12和13。2,6-二氨基嘌呤与1,4-二氯-2-丁炔的烷基化产生氯代衍生物6a,后者被水解成醇6b。6b的烯丙基异构化得到化合物5c。氯衍生物2e-g,4c-f,5d和6c-e以及嘧啶氧杂环戊烯9c和9d是IC50 10-100 microM的鼠白血病L1210的缓效抑制剂。最活跃的是类似物4c,4d,4e,和6e(IC50 10-20 microM)。相应的羟基衍生物的活性较小。用化合物4c,4d,6e,9c和9d抑制大分子合成的顺序如下:DNA大于RNA大于或等于蛋白质。四种
    DOI:
    10.1021/jm00105a064
点击查看最新优质反应信息

文献信息

  • PHADTARE, SHASHIKANT;KESSEL, DAVID;ZEMLICKA, JIRI, NUCLEOSIDES AND NUCLEOTIDES, 8,(1989) N-6, C. 907-910
    作者:PHADTARE, SHASHIKANT、KESSEL, DAVID、ZEMLICKA, JIRI
    DOI:——
    日期:——
  • PHADTARE, SHASHIKANT;KESSEL, DAVID;CORBETT, THOMAS H.;RENIS, HAROLD E.;CO+, J. MED. CHEM., 34,(1991) N, C. 421-429
    作者:PHADTARE, SHASHIKANT、KESSEL, DAVID、CORBETT, THOMAS H.、RENIS, HAROLD E.、CO+
    DOI:——
    日期:——
  • Unsaturated and carbocyclic nucleoside analogs: synthesis, antitumor and antiviral activity
    作者:Shashikant Phadtare、David Kessel、Thomas H. Corbett、Harold E. Renis、Barbara E. Court、Jiri Zemlicka
    DOI:10.1021/jm00105a064
    日期:1991.1
    activities were investigated. Alkylation of cytosine with (E)-1,4-dichloro-2-butene gave chloro derivative 2f, which was hydrolyzed to alcohol 2h. Cytosine, adenine, 2-amino-6-chloropurine, thymine, and (Z)-1,4-chloro-2-butene gave compounds 4c-f, which, after hydrolysis, afforded alcohols 4a, 4b, 4g, and 4h. Alkenes 4d and 4e were cyclized to heterocycles 12 and 13. Alkylation of 2,6-diaminopurine with
    制备了一系列核苷的不饱和类似物,并研究了它们的细胞毒性,抗肿瘤和抗病毒活性。用(E)-1,4-二氯-2-丁烯烷基化胞嘧啶,得到氯衍生物2f,将其水解成醇2h。胞嘧啶,腺嘌呤,2-氨基-6-氯嘌呤,胸腺嘧啶和(Z)-1,4-氯-2-丁烯得到化合物4c-f,水解后得到醇4a,4b,4g和4h。烯烃4d和4e环化成杂环12和13。2,6-二氨基嘌呤与1,4-二氯-2-丁炔的烷基化产生氯代衍生物6a,后者被水解成醇6b。6b的烯丙基异构化得到化合物5c。氯衍生物2e-g,4c-f,5d和6c-e以及嘧啶氧杂环戊烯9c和9d是IC50 10-100 microM的鼠白血病L1210的缓效抑制剂。最活跃的是类似物4c,4d,4e,和6e(IC50 10-20 microM)。相应的羟基衍生物的活性较小。用化合物4c,4d,6e,9c和9d抑制大分子合成的顺序如下:DNA大于RNA大于或等于蛋白质。四种
查看更多

同类化合物

阿斯普尼辛B 阿斯普尼辛 D 阿斯普尼辛 苯佐莫文 新骏河毒素 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) TAK960抑制剂 PLK1抑制剂(RO3280) 8H-嘧啶并[4,5-b][1,4]二氮杂卓 8-甲基-5,9-二氢-6H-嘧啶并[4,5-b][1,4]重氮基庚英-6-酮 6H-嘧啶并[4,5-b][1,4]二氮杂卓 4-甲基-6,11-二氢-3H-嘧啶并[4,5-b][1,5]苯并二氮杂卓-2,5-二酮 2-氯-7,7-二氟-5-甲基-5,7,8,9-四氢-6H-嘧啶基[4,5-B][1,4]二氮杂-6-酮 2-氯-5-甲基-5,7,8,9-四氢-6H-嘧啶[4,5-B][1,4]二氮杂6-酮 1H-嘧啶并[4,5-b][1,4]二氮杂卓 4-amino-8-(1,3-benzodioxol-5-yl)-6-phenyl-8,9-dihydro-7H-pyrimido[4,5-b][1,4]diazepine 2-(2-Bromo-4-isopropyl-phenyl)-4-methyl-6-pentyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 2-chloro-8-(trifluoromethyl)-6H,11H-benzo[b]pyrimidino[5,4-f]-1,4-diazaperhydroepin-5-one 4,5,6,7-tetrahydro-2,4-diphenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione 4,5,6,7-tetrahydro-4-methyl-2-phenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-2-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide di-tert-butyl (1r,4r)-4-(4-(9-cyclohexyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxybenzamido)cyclohexyl phosphate 2-(2-Bromo-4-isopropyl-phenyl)-6-(1-ethyl-propyl)-4-methyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 7,8,9,10-tetrahydro-10-hydroxy-9-heptyl-[1,4]diazepino[1,2,3-g,h]purine 7,8,9,10-tetrahydro-10-hydroxy-9-methyl-9-propyl[1,4]diazepino[1,2,3-g,h]purine 6-cyclopentyl-9-[(3-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one 6-cyclopentyl-9-[(2-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one tert-butyl 8,10-dibromo-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate tert-butyl 8,10-dimethyl-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate 11-Diallylaminoacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 6-butyl-11-diallylaminoacetyl-2-phenyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 11-chloroacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 4-[(2-cyclopentyl-4,4,6-trimethyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]benzoic acid 4-[(2-cyclopentyl-6-methyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]-3-methoxy-N-(4-piperidyl)benzamide 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-N-(1-ethyl-4-piperidyl)-3-methoxy-benzamide 8-(4-chlorophenyl)-6-phenyl-9H-pyrimido[4,5-b][1,4]diazepin-4-ol 1-chloro-7-methoxy-8-(3-morpholin-4-yl-propoxy)-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cycloheptene 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-3-methoxy-N-methyl-benzamide (S)-tert-butyl (4-chloro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-7-yl)carbamate 3-methoxy-4-[[6-(2-methoxyethyl)-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl]amino]-N-(1-methyl-4-piperidyl)benzamide (9aS,9R)-4-chloro-N-(4-methylphenyl)-9a,10,11,12-tetrahydro-9H-pyrimido[4,5-b]dipyrrolo[1,2-d:2',1'-g][1,4]diazepin-9-amine